BioMarin Pharmaceutical | BMRN - Le Bénéfice D'Exploitation





Le Bénéfice D'Exploitation Changement Date
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
Agios Pharmaceuticals USD -110.02M 11.55M 2026-03
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Amgen USD 4.61B 777M 2026-06
Bayer EUR 827M 2.7B 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Gilead Sciences USD 3.85B 1.17B 2026-06
Incyte USD 700.4M 376.22M 2026-06
Insmed USD -101.31M 98.97M 2026-06
Ionis Pharmaceuticals USD -102.29M 15.71M 2026-06
Moderna USD -815M 573M 2026-06
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
PTC Therapeutics USD 45.89M 127.51M 2026-03
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Roche Holding CHF 11.46B 1.91B 2026-06
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 2.27B 771M 2026-03
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
United Therapeutics USD 330.8M 5M 2026-06
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06